Annual report
3353.TEDINET S100Y4Y9
Period2025-03-01 → 2026-02-28
Filed2026-05-19
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 145
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥55.0bn | 2025-03-01 → 2026-02-28 | Cons. | Net sales |
| Revenue | ¥48.4bn | 2024-03-01 → 2025-02-28 | Cons. | Net sales |
| Revenue | ¥39.9bn | 2023-03-01 → 2024-02-29v | Cons. | Net sales (5-year summary) |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28v | Cons. | Net sales (5-year summary) |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.8bn | 2025-03-01 → 2026-02-28 | Cons. | Operating income |
| Operating income | ¥1.7bn | 2024-03-01 → 2025-02-28 | Cons. | Operating income |
| Ordinary income | ¥1.9bn | 2025-03-01 → 2026-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2024-03-01 → 2025-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-03-01 → 2024-02-29v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2025-03-01 → 2026-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥1.9bn | 2024-03-01 → 2025-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.3bn | 2025-03-01 → 2026-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2023-03-01 → 2024-02-29v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.3bn | 2025-03-01 → 2026-02-28 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss |
| Total assets | ¥37.6bn | at 2026-02-28 | Cons. | Assets |
| Total assets | ¥34.2bn | at 2025-02-28 | Cons. | Assets |
| Total assets | ¥31.7bn | at 2024-02-29v | Cons. | Total assets (5-year summary) |
| Total assets | ¥27.5bn | at 2023-02-28v | Cons. | Total assets (5-year summary) |
| Total assets | ¥29.1bn | at 2022-02-28d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥21.2bn | at 2026-02-28 | Cons. | Liabilities |
| Total liabilities | ¥19.5bn | at 2025-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥16.3bn | at 2026-02-28 | Cons. | Net assets |
| Net assets / equity | ¥14.7bn | at 2025-02-28 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-02-29v | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥11.9bn | at 2022-02-28d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.1bn | at 2026-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.8bn | at 2025-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.7bn | at 2026-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.6bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.8bn | at 2022-02-28d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.2bn | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.3bn | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.1bn | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.2bn | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥478m | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥216m | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥284m | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥278m | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥65m | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥338.73 | 2025-03-01 → 2026-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.35 | 2024-03-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.7 | 2023-03-01 → 2024-02-29v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,164.98 | at 2026-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,747.7 | at 2025-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,523.25 | at 2024-02-29v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,207.14 | at 2023-02-28v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,030.61 | at 2022-02-28d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 41.7% | at 2026-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.8% | at 2024-02-29v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.6% | 2025-03-01 → 2026-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2024-03-01 → 2025-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2023-03-01 → 2024-02-29v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2022-03-01 → 2023-02-28v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-03-01 → 2022-02-28d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,608 | at 2026-02-28 | Cons. | Number of employees |
| Employees | 1,547 | at 2025-02-28 | Cons. | Number of employees |
| Employees | 1,431 | at 2024-02-29v | Cons. | Number of employees |
| Employees | 1,297 | at 2023-02-28v | Cons. | Number of employees |
| Employees | 1,325 | at 2022-02-28d | Cons. | Number of employees |
| Revenue | ¥908m | 2025-03-01 → 2026-02-28 | Standalone | Operating revenue1 |
| Revenue | ¥1.3bn | 2024-03-01 → 2025-02-28 | Standalone | Operating revenue1 |
| Operating income | ¥183m | 2025-03-01 → 2026-02-28 | Standalone | Operating income |
| Operating income | ¥620m | 2024-03-01 → 2025-02-28 | Standalone | Operating income |
| Ordinary income | ¥254m | 2025-03-01 → 2026-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥680m | 2024-03-01 → 2025-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥616m | 2023-03-01 → 2024-02-29v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥592m | 2022-03-01 → 2023-02-28v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥432m | 2021-03-01 → 2022-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥247m | 2025-03-01 → 2026-02-28 | Standalone | Income before income taxes |
| Profit before tax | ¥752m | 2024-03-01 → 2025-02-28 | Standalone | Income before income taxes |
| Net income | ¥166m | 2025-03-01 → 2026-02-28 | Standalone | Profit loss |
| Net income | ¥616m | 2024-03-01 → 2025-02-28 | Standalone | Profit loss |
| Net income | ¥457m | 2023-03-01 → 2024-02-29v | Standalone | Net income loss (5-year summary) |
| Net income | ¥526m | 2022-03-01 → 2023-02-28v | Standalone | Net income loss (5-year summary) |
| Net income | ¥397m | 2021-03-01 → 2022-02-28d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥12.6bn | at 2026-02-28 | Standalone | Assets |
| Total assets | ¥13.1bn | at 2025-02-28 | Standalone | Assets |
| Total assets | ¥12.7bn | at 2024-02-29v | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2023-02-28v | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.5bn | at 2022-02-28d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.4bn | at 2026-02-28 | Standalone | Liabilities |
| Total liabilities | ¥3.7bn | at 2025-02-28 | Standalone | Liabilities |
| Net assets / equity | ¥9.2bn | at 2026-02-28 | Standalone | Net assets |
| Net assets / equity | ¥9.4bn | at 2025-02-28 | Standalone | Net assets |
| Net assets / equity | ¥9.0bn | at 2024-02-29v | Standalone | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-02-28v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.3bn | at 2022-02-28d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥356m | at 2026-02-28 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-02-28 | Standalone | Cash and deposits |
| EPS (basic) | ¥43.98 | 2025-03-01 → 2026-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.72 | 2024-03-01 → 2025-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.61 | 2023-03-01 → 2024-02-29v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.07 | 2022-03-01 → 2023-02-28v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.69 | 2021-03-01 → 2022-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥120 | 2025-03-01 → 2026-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥65 | 2024-03-01 → 2025-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2023-03-01 → 2024-02-29v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2022-03-01 → 2023-02-28v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-03-01 → 2022-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,450.13 | at 2026-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,498.76 | at 2025-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,385.18 | at 2024-02-29v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,293.7 | at 2023-02-28v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,196.84 | at 2022-02-28d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 73.1% | at 2026-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.0% | at 2025-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2024-02-29v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.2% | at 2023-02-28v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2022-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.8% | 2025-03-01 → 2026-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2024-03-01 → 2025-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.2% | 2023-03-01 → 2024-02-29v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2022-03-01 → 2023-02-28v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2021-03-01 → 2022-02-28d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,770,000 | at 2026-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2025-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2024-02-29v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2023-02-28v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2022-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 30 | at 2026-02-28 | Standalone | Number of employees |
| Employees | 30 | at 2025-02-28 | Standalone | Number of employees |
| Employees | 22 | at 2024-02-29v | Standalone | Number of employees |
| Employees | 25 | at 2023-02-28v | Standalone | Number of employees |
| Employees | 25 | at 2022-02-28d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 86
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-03-01 → 2026-02-28 | ¥175m |
| Reconciling Itemsreconciling | depreciation | 2025-03-01 → 2026-02-28 | ¥44m |
| Reconciling Itemsreconciling | revenue | 2025-03-01 → 2026-02-28 | −¥1.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-03-01 → 2026-02-28 | −¥1.2bn |
| Reconciling Itemsreconciling | segment assets | at 2026-02-28 | ¥10.0bn |
| Reconciling Itemsreconciling | segment profit | 2025-03-01 → 2026-02-28 | −¥129m |
| Dispensing Pharmacyreportable segment | capex | 2025-03-01 → 2026-02-28 | ¥212m |
| Dispensing Pharmacyreportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥184m |
| Dispensing Pharmacyreportable segment | employees | at 2026-02-28 | 500 pure |
| Dispensing Pharmacyreportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥26.3bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥26.3bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2026-02-28 | ¥7.4bn |
| Dispensing Pharmacyreportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥1.4bn |
| Health Carereportable segment | capex | 2025-03-01 → 2026-02-28 | ¥117m |
| Health Carereportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥410m |
| Health Carereportable segment | employees | at 2026-02-28 | 833 pure |
| Health Carereportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥9.0bn |
| Health Carereportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥9.0bn |
| Health Carereportable segment | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥800,000 |
| Health Carereportable segment | segment assets | at 2026-02-28 | ¥10.7bn |
| Health Carereportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥112m |
| Medical Products Wholesalereportable segment | capex | 2025-03-01 → 2026-02-28 | ¥38m |
| Medical Products Wholesalereportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥25m |
| Medical Products Wholesalereportable segment | employees | at 2026-02-28 | 243 pure |
| Medical Products Wholesalereportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥20.6bn |
| Medical Products Wholesalereportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥19.4bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥1.2bn |
| Medical Products Wholesalereportable segment | segment assets | at 2026-02-28 | ¥6.7bn |
| Medical Products Wholesalereportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥287m |
| Real Estatereportable segment | capex | 2025-03-01 → 2026-02-28 | ¥3m |
| Real Estatereportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥59m |
| Real Estatereportable segment | employees | at 2026-02-28 | 1 pure |
| Real Estatereportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥265m |
| Real Estatereportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥254m |
| Real Estatereportable segment | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥11m |
| Real Estatereportable segment | segment assets | at 2026-02-28 | ¥2.8bn |
| Real Estatereportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥145m |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-03-01 → 2026-02-28 | ¥369m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-03-01 → 2026-02-28 | ¥678m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-03-01 → 2026-02-28 | ¥56.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-03-01 → 2026-02-28 | ¥55.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-02-28 | ¥27.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-03-01 → 2026-02-28 | ¥1.9bn |
| Reconciling Itemsreconciling | capex | 2024-03-01 → 2025-02-28 | ¥61m |
| Reconciling Itemsreconciling | depreciation | 2024-03-01 → 2025-02-28 | ¥36m |
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2025-02-28 | −¥846m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2025-02-28 | −¥846m |
| Reconciling Itemsreconciling | segment assets | at 2025-02-28 | ¥9.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2025-02-28 | −¥188m |
| Dispensing Pharmacyreportable segment | capex | 2024-03-01 → 2025-02-28 | ¥200m |
| Dispensing Pharmacyreportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥187m |
| Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥24.7bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥24.7bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2025-02-28 | ¥7.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥1.2bn |
| Health Carereportable segment | capex | 2024-03-01 → 2025-02-28 | ¥790m |
| Health Carereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥349m |
| Health Carereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥8.1bn |
| Health Carereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥8.1bn |
| Health Carereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥600,000 |
| Health Carereportable segment | segment assets | at 2025-02-28 | ¥9.4bn |
| Health Carereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥163m |
| Medical Products Wholesalereportable segment | capex | 2024-03-01 → 2025-02-28 | ¥23m |
| Medical Products Wholesalereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥11m |
| Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥16.2bn |
| Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥15.4bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥841m |
| Medical Products Wholesalereportable segment | segment assets | at 2025-02-28 | ¥6.1bn |
| Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥345m |
| Real Estatereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥42m |
| Real Estatereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥208m |
| Real Estatereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥204m |
| Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥5m |
| Real Estatereportable segment | segment assets | at 2025-02-28 | ¥2.1bn |
| Real Estatereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥138m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-03-01 → 2025-02-28 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-03-01 → 2025-02-28 | ¥589m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2025-02-28 | ¥49.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2025-02-28 | ¥48.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥846m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-02-28 | ¥25.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2025-02-28 | ¥1.9bn |
| Dispensing Pharmacyreportable segment | employees | at 2026-02-28 | 2 pure |
| Health Carereportable segment | employees | at 2026-02-28 | 1 pure |
| Real Estatereportable segment | employees | at 2026-02-28 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,671
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人 トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)神 野 敦 生 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)牧 野 秀 俊 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)伊 藤 貴 俊 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)調剤薬局事業及びヘルスケア事業に係る有形固定資産の減損 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項(重要な会計上の見積り) | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人 トーマツ | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)神 野 敦 生 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)牧 野 秀 俊 | |
| Cpa3 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)伊 藤 貴 俊 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)関係会社投融資の評価 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 33595990000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 33897598000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 39900988000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 48393487000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 54982518000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 1357878000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 1227454000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 1751894000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1816093000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 1859020000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 852328000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 759598000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 1039786000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1133165000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 1275072000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 838275000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 827629000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 1381275000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1050280000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 1992252000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 11927858000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant | 12607842000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant | 13841190000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 14712134000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |